Bivalirudin benefits in bleeding events versus heparin plus glycoprotein IIbIIIa inhibitors is clear even though this benefit has not been fully studied at the point whether persists when glycoprotein inhibitors are used only for rescue and not routinely.
This is an EUROMAX sub-analysis that included 2198 patients experiencing AMI analyzing events at 30 days. Bivalirudin was superior to heparin whether the glycoprotein IIbIIIa inhibitors were used routinely or as rescue.
U. Zeymer
2014-05-22
Title: Routine bivalirudin is superior to unfractionated heparin and bailout glycoprotein IIb/IIIa inhibitors in patients with STEMI transported
